Previous close | 11.30 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 262 |
Market cap | 7.461M |
Beta (5Y monthly) | 0.53 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The transaction, which took place on December 31, 2023, involved the acquisition of 75,537 shares at a trade price of $8.14 per share. This strategic move has expanded Viking Global's holding to a total of 2,531,829 shares in Verastem Inc, reflecting the firm's confidence in the company's future prospects.
On February 6, 2024, Robert Gagnon, a director at Verastem Inc, executed a sale of 9,204 shares of the company.
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.